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Abstract
This is a report on a 37-patient continuation study of the open ended, Omega-3 Fatty Acid (O-3FA)
add-on study. Subjects consisted of the original 19 patients, along with 18 new patients recruited
and followed in the same fashion as the first nineteen. Subjects carried a DSM-IV-TR diagnosis of
Bipolar Disorder and were visiting a Mood Disorder Clinic regularly through the length of the
study. At each visit, patients' clinical status was monitored using the Clinical Monitoring Form.
Subjects reported on the frequency and severity of irritability experienced during the preceding ten
days; frequency was measured by way of percentage of days in which subjects experienced
irritability, while severity of that irritability was rated on a Likert scale of 1 – 4 (if present). The
irritability component of Young Mania Rating Scale (YMRS) was also recorded quarterly on 13 of
the 39 patients consistently. Patients had persistent irritability despite their ongoing pharmacologic
and psychotherapy.
Omega-3 Fatty Acid intake helped with the irritability component of patients suffering from bipolar
disorder with a significant presenting sign of irritability. Low dose (1 to 2 grams per day), add-on
O-3FA may also help with the irritability component of different clinical conditions, such as
schizophrenia, borderline personality disorder and other psychiatric conditions with a common
presenting sign of irritability.

Introduction
According to the United States National Institute of Mental Health (NIMH), Bipolar Disorder (BPD), also known
as manic-depressive illness, is a serious medical illness
that causes shifts in a person's mood, energy, and ability
to function. Different from the normal ups and downs

that everyone goes through, the symptoms of bipolar disorder are severe. Bipolar disorder is a complex, chronic
condition associated with considerable morbidity and
mortality, including a high rate of suicide. Bipolar disorder causes dramatic mood swings from overly "high" and/
or irritable to sad and hopeless, and then back again, often
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with periods of normal mood in between. Severe changes
in energy and behavior go along with these changes in
mood. The periods of highs and lows are called episodes
of mania and depression. Most people with bipolar disorder can achieve substantial stabilization of their mood
swings and related symptoms over time with proper treatment. A strategy that combines medication and psychosocial treatment is optimal for managing the disorder over
time.

Background
Omega-3 fatty acids (0-3FA) may have a beneficial effect
on irritable mood. Low O-3FA levels in red blood cell
membranes of depressed patients hint that O-3FA may be
helpful in treating mood disorders [1]. A recent article has
given an excellent review of O-3FA and studies showing
their effectiveness in depression, bipolar disorder and
aggression [2]. In this article, two published studies are
discussed that have reported on similar therapeutic effects
of O-3FA [2]. One placebo-controlled study of 20 patients
revealed that ethyl ester of eicosapentaenoic acid (E-EPA)
was effective in stabilizing the moods of depressed
patients [3]. Another report, a double-blind, placebo controlled study (N = 22/19), measured the effect of O-3FA
docosahexaenoic acid (DHA) on the aggressive tendencies
of college students. The O-3FA DHA group (1.5–1.8 g OFA DHA/day) did not display any increase in aggressive
tendencies when external stressors peaked, while the placebo group displayed a significant increase in their aggressive tendencies under similar circumstances [4]. In a
recent study, 25% of 111 patients with bipolar-I disorder
who met criteria for a DSM-IV major depressive episode
also experienced substantial irritability in the absence of
associated symptoms of mania. These findings suggest
that abnormal irritability is not limited to mania or mixed
states [5]. However, recent studies give caution that at a 6
gram per day average daily dose, as a single agent, omega
3 fatty acids may not be as effective as an antidepressant
[6-9].
O-3FA may also help with the irritability component of
different clinical conditions, such as depression, mania,
schizophrenia, borderline personality disorder and other
psychiatric conditions with a common presenting sign of
irritability. Numerous other conditions have an irritability
component, including Borderline Personality Disorder,
Alzheimer's disease, Premenstrual Dysphoric Disorder, to
name a few [10-12]. There is one report suggesting beneficial effect of Omega-3 Fatty acid treatment for Borderline
Personality Disorder. This double-blind, placebo-controlled pilot study specifically showed that EPA may influence
both aggression and depression [12]. Although attentiondeficit/hyperactivity disorder (ADHD) also has an irritability component, recent publications bring doubt to the
O3FA connection in ADHD [13,14].
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A recent, open ended, O-3FA add-on study has shown
beneficial effect of O-3FA on irritability in 19 patients
with mood disorders [15]. These patients had already
been receiving different combinations of pharmacotherapy and talk therapy. Despite their treatment, the irritability component of their illness was still causing social,
occupational and other life disturbances. Hence, they
were chosen for the O-3FA add-on component of the
study. In the nineteen-patient phase of the study, bipolar
patients of every subtype, ages 18 to 65 years, with significant irritability were studied. All patients received a systematic assessment battery at entry and were treated by a
psychiatrist, trained to deliver care and measure outcomes
in patients with bipolar disorder, consistent with expert
recommendations. At every follow-up visit, the treating
psychiatrist completed a standardized assessment and
assigns a clinical status based on DSM-IV criteria. Patients
had independent evaluations at regular intervals throughout the study and remain under the care of the same treating psychiatrist while receiving variable medications and
talk therapy, depending on their need [15]. In the 19patient study, a paired sample t-test revealed a large
decrease in the percent of days irritable after O-3FA was
administered. Before treatment, the mean irritability percentage was 81.05 (SD = 23.31) and after treatment the
mean irritability percentage dropped to 30.00 (SD =
36.67). Despite the small number of patients in the study
(n = 19), the difference between means was statistically
significant (t (18) 4.512, p < .001). Using a paired sample
t-test, a significant difference was also found between the
highest irritability score (mean = 2.79; SD = 0.92) and the
last recorded irritability (mean = 0.79; SD = 0.85) while
taking O-3FA (t(18) = 8.270; p < .001) [15].

Methods
This is a report on a 37-patient continuation phase of the
open ended, O-3FA add-on study. Subjects consisted of
the original 19 patients, in addition to the 18 new patients
recruited and followed in the same fashion as the first
nineteen [15]. Subjects carried a DSM-IV-TR [16] diagnosis of Bipolar Disorder and were visiting a Mood Disorder
Clinic regularly throughout the length of the study. At
each visit, patients' clinical status was monitored using the
Clinical Monitoring Form [17]. Subjects reported on the
frequency and severity of irritability experienced during
the preceding ten days; frequency was measured by way of
percentage of days in which subjects experienced irritability, while severity of that irritability was rated on a Likert
scale of 1 – 4 (if present). The irritability component of
Young Mania Rating Scale [18] (YMRS) was also recorded
quarterly on 13 of the 39 patients consistently. The
patients were asked about general dietary omega-3 intake
before the fish oil was added on, and basic nutritional
guidance was given to subjects at the clinic. Patients in
general were not heavy fish/product consumers.
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Table 1: Initial, Last and Final Omega 3 Dosages (mg). summarizes dosage under three conditions. Figures for the Initial Dose include
two subjects (n = 39) for whom no corresponding follow-up data were available.

Initial, Last Recorded and Final Omega 3 Dosages (mg)

n
Mean
Mode
Median
SD

Initial

Last Recorded

FinalT1

39
1833.33
1000T2, T3
2000
1071.91

37
2878.38
1000
2000
2011.79

13
2615.38
2000
2000
1894.66

T1 = Final group results (n = 13) are discussed below.
T2 = Multiple modes exist. The smallest value is shown.
T3 = One gram (1,000 miligram) of fish oil; of which about 180 milligrams is (eicosapentaenoic acid) EPA and 120 milligrams is DHA
(docosahexaenoic acid), (for a total of 300 milligrams of omega 3's) in each clear capsule.

Dosage
Starting dose and last maintenance dose were available for
37 subjects (Table 1). Subjects self-medicated, and therefore, the last maintenance dose of O-3FA was chosen by
each subject. The mean starting dose was 1824.32 mg (SD
1075.07), and the mean for the last maintenance dose
was considerably higher at 2878.38 mg (SD 2011.79). The
increase was statistically significant using a paired sample
t-test (t = -3.44, 36df, p = .001).

The decrease found to be statistically significant using a
paired sample t-test (t = 4.14, 33 df, p < .001).
Severity
Thirty six subjects had initial and last recorded severity
scores on the ADE. Again, a decrease was found. The initial mean score was 2.14 (SD 1.22). The mean for the last
recorded score was 0.94 (SD 0.92). This decrease was
found to be statistically significant using a paired sample
t-test (t = 5.23, 35 df, p < .001).

Statistical Results
Percentage of Irritable (Days)
The initial mean was 63.51 (SD 34.17), indicating that on
average, subjects were irritable for about six of the previous ten days. The mean for the last recorded percentage
was less than half of the initial score: 30.27 (SD 34.03).
The decrease was found to be statistically significant using
a paired sample t-test (t = 4.36, 36 df, p < .001). The difference between the distributions was examined using the
non-parametric sign test. The number of negative differences (25) significantly exceeded positive differences (7);
there were five ties, and the pre/post distributions were
significantly different (p < .003).

Composite: Severity and Irritability
As an exploratory measure, a composite score was created
by multiplying the ADE severity score, which has a maximum of 4 points, by the percentage of the ten days prior
to measurement which the patient was rated as irritable.
The initial mean on this composite was 159.72. As with
other measures, there was wide variation: SD = 122.92.
The mean for this measure on the last recorded scores was
percentage was about one-fourth of the initial score: 43.89
(SD 64.38). The decrease was found to be statistically significant using a paired sample t-test (t = 5.00, 35 df, p <
.001).

YMRS Irritability Sub-score
Thirty four subjects had initial and last recorded YMRS
irritability sub-scores. As with the above means there was
a sizable decrease. The initial mean score was 3.18 (SD
1.09). The mean for the last recorded percentage was 1.68
(SD 1.89). The decrease was found to be statistically significant using a paired sample t-test (t = 4.21, 33 df, p <
.001).

Last Recorded Maintenance Dose and Percentage of
Irritability After
Because of apparent wide variation on these two measures
and a concern that outliers may have affected some
results, the last recorded irritability scores were plotted
against the maintenance dose. This revealed a rather
bimodal pattern, in which relatively lower irritability
measures (≤ 50%) clustered in the quadrant with lower
dosage levels (≤ 4,000 mg).

YMRS Total Score
Starting and last recorded YMRS scores were available for
34 subjects. The mean starting score 10.71 (SD 6.77), and
the mean for the last recorded score was 4.85 (SD 5.63).

Duration and YMRS Total
In response to a similar observation regarding wide variation in the last recorded values (84 days to 5.5 years) the
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values were also plotted. A clearly bimodal pattern
appeared in which 11 subjects (about one-third of study
participants) clustered in the quadrant representing short
duration (<500 days) and higher YMRS totals (>7). The
remaining two-thirds of subjects clustered in the quadrant
representing short duration and lower YMRS totals (<6).

http://www.nutritionj.com/content/4/1/6

104.19. The mean for this measure on the last recorded
scores was percentage was much lower that the initial
score: 33.08 (SD 39.87). The decrease was found to be statistically significant using a paired sample t-test (t = 6.70,
12 df, p < .001).

Subject Weight
The mean start weight was 176.97 lbs (SD 43.13), and the
mean for the last weight recorded was slightly higher at
178.59 lbs (SD 43.24). The increase was not statistically
significant.

Weight
For these 13 subjects, the mean start weight was 166.23
lbs (SD 35.68), and the mean for the final weight recorded
was also slightly higher at 168.23 lbs (33.62). As with the
previous finding regarding weight, the increase was not
statistically significant.

Follow-up Subjects

Results

Follow-up information, recorded after the collection of
the "last" scores for most of the above variables, was available for 13 of the 37 subjects. Final YMRS total or scale
scores were not available for this sub-group.

Omega-3 Fatty Acids added onto the existing treatment
helped with the irritability component of a significant percentage of patients suffering from bipolar disorder with a
persistent sign of irritability.

Omega 3 Duration
The final date recorded for the duration of O3 was derived
based from an O3 start date and a "final" date recorded for
O3. The time period ranged 84 days to 1995 days (5.46
years). The mean duration of O3 for this group was
439.62 days (SD = 487.46).

Discussion

Dosage
For these subjects, the mean starting dose was 1807.69 mg
(SD 990.34), and the mean for the last maintenance dose
was higher at 2615.38 mg (SD 1894.66). The increase was
not significant.

As seen from the standard deviations of several of the variables discussed here, measures ranged widely. This creates difficulty in using descriptive data, such as means, to
adequately portray subject attributes and performance.
Using data reduction techniques or grouping subjects
according to high and low scores on various attributes
may be one way to increase the descriptiveness, which
would be possible and more reasonable with a larger pool
of subjects.

Percentage Irritable (Days)
The initial mean was 82.31 (SD 20.88). The mean for the
last recorded percentage was dramatically lower: 25.38
(SD 32.04). The decrease was found to be statistically significant using a paired sample t-test (t = 6.52 12 df, p <
.001). The difference between the distributions was examined using a sign test. The number of negative differences
(12) significantly exceeded positive differences (0); there
was one tie, and the pre/post distributions were significantly different (p < .001).

A potential limitation or interpretive consideration merits
discussion. For many of the variables discussed above,
noticeable differences in measures were observed between
the "starting" versus "last recorded" group (n = 37) and
the "starting" versus "final" measures group (n = 13).
Given these differences and the smaller number of subjects in the second set of comparisons, "starting" versus
"final" comparisons should be interpreted with caution
until differences inherent in this "final" subgroup (n = 13)
are more clearly understood. This is clearly seen in the
results of sign tests, in which the apparent magnitude of
the "final" effects is pronounced.

Severity
The initial mean score for the 13 subjects with final scores
was 2.69 (SD 0.95). The mean for the final score was 0.77
(SD 0.83). This decrease was found to be statistically significant using a paired sample t-test (t = 6.22, 12 df, p <
.001).

Statistically significant within-subjects differences were
found in several independent variables. This is especially
notable given the small number of subjects. The preliminary findings suggest that a rigorously designed study tailored especially to the examination of the effects of O-3FA
is warranted.

Composite: Severity and Irritability
An exploratory composite score, described above, was
also created for the subjects with final scores. For these
subjects, the initial mean was higher than that of the total
group, 223.08. Again, there was wide variation: SD =

The majority of data were collected within an ongoing
"best-practice, outpatient bipolar disorder study" that
involved medications and talk therapy which we have not
reported or discussed herein. Results must, therefore, be
interpreted with caution.
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There are several mechanisms through which O-3FA are
theorized to help with mood, irritability, aggression etc.
Suggested theories of mechanism converge on the theory
of nerve cell membrane stabilization. A recent study has
come closest to showing physical proof of effectiveness of
O-3FA through indirect demonstration of greater membrane fluidity, as detected by reductions in Tesla-2 (T2)
values in MRI scans [19]. The overlapping beneficial
effects of antipsychotics, antidepressants, anticonvulsants,
O-3FA, and nonpsychoactive cannabinoids, as they relate
to pain, stroke, schizophrenia, psychoneuroimmunology,
Alzheimer's disease, and stress, may be because of their
common effects at protein kinases, thus affecting the
structure and function of the cell membrane and the cell
[20]. These changes should help the cell operate within an
optimal level of excitation, which may be related to
emerging evidence that these therapeutic agents have neuroprotective value [20]. A recent randomized placebo controlled double blind intervention study suggests an
adaptogenic role for O-3FA in stress [21].
We would like to discuss briefly the issue of daily dosing
of O-3FA for nutrition and medicinal purpose: Recent
studies give caution that at a 6 gram per day average daily
dose, as a single agent, omega 3 fatty acids may not be as
effective as an antidepressant [6-9]. However, these studies may have given too high of a dose of O-3FA, above 6
grams daily, with possibly beyond a therapeutic window
of effectiveness for O-3FA. Our scatter plots indicate that
the optimum effective dose for irritability is at 1–2 gram
of EPA plus DHA per day, which would be the dosing we
suggest. A recent exploratory dose study of O-3FA for
schizophrenic patients showed that 2 g/day EPA-treated
patients had lower symptom scores, and needed less medication greatest. In this study, there was a positive relationship between improvement on rating scales and rise in red
blood cell arachidonic acid concentration as well [22].

http://www.nutritionj.com/content/4/1/6

We conclude that it is beneficial in many ways to establish
a regular intake of 1–2 g per day EPA acid plus DHA, similar to daily intake of vitamins with minerals. Dietary
interventions to remedy omega-3 deficiency is necessary
[23]. It is time for more aggressive funding for research
into medicinal foods, such as omega-three fatty acids [23].
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